Assistant Prof of Cardiothoracic Surgery @UABmedicine. Specializing in Structural Heart/TAVR, Aortic Surgery, Aortic Valve Repair, & Hybrid/Endo Aortic Repair
- Tweets988
- Following513
- Followers1.8K
- Likes5.5K
ALT A detailed illustration of infective endocarditis on the left side of the heart. Accompanying the heart image are pills, medication bottles, a box, and a monthly calendar.
ALT A graph from the Original Article "Intermittent or Continuous Renal-Replacement Therapy in Acute Kidney Injury." The trial name, ICRAKI, is in parentheses after the title. The graph shows the cumulative probability of death from randomization through day 90, as estimated with the Kaplan–Meier method. The trial results are being presented at the European Society of Intensive Care Medicine. The logo of the New England Journal of Medicine is at the bottom.
ALT Three graphs showing Kaplan–Meier estimates for prespecified events as adjudicated by the clinical-events committee at 3 years. Panel A shows freedom from death from any cause or hospitalization for heart failure (second coprimary end point), Panel B survival, and Panel C freedom from hospitalization for heart failure.
ALT Two figures showing the effect of retatrutide on body weight. Panel A shows the percent change in body weight from baseline to week 80 (controlled for type I error). Panel B shows the percentage of patients with reductions in body weight of 15% or more and 30% or more (controlled for type I error), along with the percentage of patients who reached the body-mass index targets of less than 30 or less than 25 and the waist-to-height ratio target of less than 0.5 (not controlled for type I error) at week 80 for the treatment-regimen estimand.
![Two figures showing the effect of retatrutide on health outcomes. Panel A shows the percent change in lipid measures, the percent change in the high-sensitivity C-reactive protein (hsCRP), and the change in systolic blood pressure (SBP) in the overall trial population (controlled for type I error except for low-density lipoprotein [LDL] and high-density lipoprotein [HDL]). Panel B shows the percentage of patients with normoglycemia, prediabetes, and type 2 diabetes at week 80 among the patients who had prediabetes at baseline for the treatment-regimen data-points set.](https://pbs.twimg.com/media/HTfI1qcWoAAnkzQ.png?name=orig)
ALT Two figures showing the effect of retatrutide on health outcomes. Panel A shows the percent change in lipid measures, the percent change in the high-sensitivity C-reactive protein (hsCRP), and the change in systolic blood pressure (SBP) in the overall trial population (controlled for type I error except for low-density lipoprotein [LDL] and high-density lipoprotein [HDL]). Panel B shows the percentage of patients with normoglycemia, prediabetes, and type 2 diabetes at week 80 among the patients who had prediabetes at baseline for the treatment-regimen data-points set.
ALT A graph from an Original Article published in the New England Journal of Medicine article titled "Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity." The graph shows effect of retatrutide on body weight. The trial name, TRIUMPH-1, is in parentheses after the title. The NEJM identity sits at the bottom.
ALT This image contains an excerpt from the Research Summary "Complete Revascularization and Coronary Angiography in STEMI" published in the New England Journal of Medicine. It includes patient demographics, presenting a mean age of 66 with 76% men and 24% women. An illustration highlights STEMI and multivessel disease. Two groups are compared: physiology-guided (N=913) and angiography-guided (N=910). A prompt to read the full Research Summary at NEJM.org sits at the bottom.
